Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Says Pfizer Inc representative Bryan Supran stepped down as a non-executive director on the Haleon board on Tuesday, following the reduction of Pfizer’s stake in Haleon to less than 10%, and in line with the two firms’ prior relationship agreement.
Haleon Chair Dave Lewis says: ‘On behalf of the board, I would like to thank Bryan for his contributions to the board’s discussions and for being part of the Haleon journey from the initial joint-venture in 2019 through demerger to today. We wish him all the very best for the future.’
Current stock price: 396.50 pence, down 0.1% in London on Tuesday afternoon
12-month change: up 22%
Copyright 2025 Alliance News Ltd. All Rights Reserved.